购物车
您的购物车当前为空
别名 辛妥珠单抗, GS 6624, AB 0024
Simtuzumab 是一种针对赖氨酰氧化酶样蛋白 2 (LOXL2) 的单克隆抗体。Simtuzumab 可用于治疗原发性硬化性胆管炎 (PSC),对非酒精性脂肪性肝炎引起的桥接性纤维化或代偿性肝硬化患者无效 。

为众多的药物研发团队赋能,
让新药发现更简单!
Simtuzumab 是一种针对赖氨酰氧化酶样蛋白 2 (LOXL2) 的单克隆抗体。Simtuzumab 可用于治疗原发性硬化性胆管炎 (PSC),对非酒精性脂肪性肝炎引起的桥接性纤维化或代偿性肝硬化患者无效 。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,650 | 现货 | |
| 5 mg | ¥ 4,970 | 现货 | |
| 10 mg | ¥ 6,880 | 现货 | |
| 25 mg | ¥ 9,870 | 现货 | |
| 50 mg | ¥ 13,700 | 现货 | |
| 100 mg | ¥ 18,500 | 现货 |
| 产品描述 | Simtuzumab is a monoclonal antibody against lysyl oxidase-like protein 2 (LOXL2). Simtuzumab can be used to treat primary sclerosing cholangitis (PSC) and is not effective in patients with bridging fibrosis or compensatory cirrhosis caused by non-alcoholic steatohepatitis. |
| 别名 | 辛妥珠单抗, GS 6624, AB 0024 |
| 反应种属 | Human |
| 验证活性 | Immobilized Human LOXL2 Protein (His) at 2 μg/mL (30 μL/well) can bind Simtuzumab. The EC50 is 38.57 ng/mL. ![]() |
| 应用 | ELISA FCM Functional assay |
| 抗体种类 | Monoclonal |
| 内毒素 | < 1 EU/mg as determined by the LAL method |
| 同型 | Human IgG4SP kappa |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| 基因ID | |
| Uniprot ID | |
| 靶点 | LOXL2 |
| 分子量 | 150.00 kDa |
| CAS No. | 1318075-13-6 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多